| 11-08-2011 05:52 AM CET - Health & Medicine |
|
Prevtec microbia closes a $4 million financing round with North-American and European investors
Press release from: Prevtec microbia
(openPR) - Prevtec microbia inc., a rapidly expanding Canadian biotech company developing innovative animal health technologies for the livestock industry, announced that it has closed a $4 million financing round from a global syndicate of financial and industry leaders.
The proceeds will mostly be used to fund the European certification process of Prevtec microbia's products, thus supporting the company's strategic plan calling for the certification and sale of 4 of its products in 12 countries on 3 continents by 2015.
The financing was led by Telesystem, globally recognized for leveraging technology and entrepreneurship to grow sustainable businesses in diverse and promising fields. Telesystem has been investing in Prevtec microbia through ID Capital Management since 2007.
This round of financing, which was concluded with the help of the Trifermed Group, allowed two new investors to join the capital of Prevtec microbia.
Infu Capital, the diversification investment arm of Grupo Fuertes, a leading European agrifood group of some 20 companies employing over 5 500 people and generating over € 1 billion in revenue, invested in this round and may increase its participation in the future.
This financing also includes a first investment from Echo Capital Fier Outaouais, as well as continuing financial support from current investor Accès Capital in Québec.
"This third round of funding is yet another testimony of the quality of the work of the research team at Prevtec and the merits of our strategic plan for bringing our innovations to the world", stated Michel Fortin, President and CEO of Prevtec microbia. "We are thrilled to have the endorsement and support of Grupo Fuertes, which is one of the largest players in the European swine industry, with a completely integrated production chain."
“Current shareholders strongly believe in the strategic plan of the company,” commented Jean-Paul Tardif, Managing Partner and Vice President Business Valuation of Telesystem. "The strength and caliber of the international partnerships Prevtec microbia is building empowers the company to become a world leader in its field.”
Prevtec microbia specializes in technologies and products adressing the swine, poultry and cattle industries, that improve animal health, increase production performance and food safety.
A leader in alternative technologies to antibiotics in food animal production, Prevtec microbia builds strategic alliances and partnerships to develop, produce, market and distribute its products worldwide, under its own brand.
Its first product, Coliprotec has been commercialized in Canada since 2008. It was also introduced in Brazil in 2011, through a distribution agreement with Virbac, the 8th largest veterinarian pharmaceutical group worldwide. Coliprotec should be available in the USA and Mexico in 2012 and in Europe in 2014. Other products are planned to be introduced in the market worldwide between 2013 and 2015.
For more information about Prevtec microbia and its products, please visit: www.prevtecmicrobia.com
For more information about our partners, please visit their websites:
telesystem.ca/
www.grupofuertes.com/
www.acces-capital.ca/
www.echocapital.ca/
www.trifermed.com/
For additional information, please contact:
Michel Fortin
President CEO
+1 514 397 8491
mfortin@prevtecmicrobia.com
Prevtec microbia inc.
1250, boul. René-Lévesque Ouest, 38e étage
Montréal (Québec)
Canada H3B 4W8
The proceeds will mostly be used to fund the European certification process of Prevtec microbia's products, thus supporting the company's strategic plan calling for the certification and sale of 4 of its products in 12 countries on 3 continents by 2015.
The financing was led by Telesystem, globally recognized for leveraging technology and entrepreneurship to grow sustainable businesses in diverse and promising fields. Telesystem has been investing in Prevtec microbia through ID Capital Management since 2007.
This round of financing, which was concluded with the help of the Trifermed Group, allowed two new investors to join the capital of Prevtec microbia.
Infu Capital, the diversification investment arm of Grupo Fuertes, a leading European agrifood group of some 20 companies employing over 5 500 people and generating over € 1 billion in revenue, invested in this round and may increase its participation in the future.
This financing also includes a first investment from Echo Capital Fier Outaouais, as well as continuing financial support from current investor Accès Capital in Québec.
"This third round of funding is yet another testimony of the quality of the work of the research team at Prevtec and the merits of our strategic plan for bringing our innovations to the world", stated Michel Fortin, President and CEO of Prevtec microbia. "We are thrilled to have the endorsement and support of Grupo Fuertes, which is one of the largest players in the European swine industry, with a completely integrated production chain."
“Current shareholders strongly believe in the strategic plan of the company,” commented Jean-Paul Tardif, Managing Partner and Vice President Business Valuation of Telesystem. "The strength and caliber of the international partnerships Prevtec microbia is building empowers the company to become a world leader in its field.”
Prevtec microbia specializes in technologies and products adressing the swine, poultry and cattle industries, that improve animal health, increase production performance and food safety.
A leader in alternative technologies to antibiotics in food animal production, Prevtec microbia builds strategic alliances and partnerships to develop, produce, market and distribute its products worldwide, under its own brand.
Its first product, Coliprotec has been commercialized in Canada since 2008. It was also introduced in Brazil in 2011, through a distribution agreement with Virbac, the 8th largest veterinarian pharmaceutical group worldwide. Coliprotec should be available in the USA and Mexico in 2012 and in Europe in 2014. Other products are planned to be introduced in the market worldwide between 2013 and 2015.
For more information about Prevtec microbia and its products, please visit: www.prevtecmicrobia.com
For more information about our partners, please visit their websites:
telesystem.ca/
www.grupofuertes.com/
www.acces-capital.ca/
www.echocapital.ca/
www.trifermed.com/
For additional information, please contact:
Michel Fortin
President CEO
+1 514 397 8491
mfortin@prevtecmicrobia.com
Prevtec microbia inc.
1250, boul. René-Lévesque Ouest, 38e étage
Montréal (Québec)
Canada H3B 4W8
News-ID: 199516
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
Prevtec microbia
No further reports available
Comments about openPR
OpenPR ist the nicest and most clearly laid out PR platform I have seen to this day. The press releases are displayed very nicely and clearly and without any unnecessary frills.
The updates are fast and the finished release looks appealing and is clearly legible.
Even with 16 years of experience one discovers new things from time to time.
Congratulations!
Gabriele Ketterl,Director Marketing & PR, Menads
The updates are fast and the finished release looks appealing and is clearly legible.
Even with 16 years of experience one discovers new things from time to time.
Congratulations!
Gabriele Ketterl,Director Marketing & PR, Menads


